The financials
Immunome, Inc. by the numbers
Immunome, Inc. (IMNM) reported revenue of $5.5M in Q1 2026 (quarter ended Mar 31, 2026), up 88% from the same quarter a year earlier. That came with net loss of $54M. For the full year FY2025, revenue was $6.9M (−23% year on year) and net income −$212M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $5.5M | $2.9M | +88% |
| Operating income | −$59M | −$45M | n/a |
| Net income | −$54M | −$42M | n/a |
| Diluted EPS | −$0.48 | −$0.52 | n/a |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2025Total $4.0M (+37%)
Single Reportable grew +70% year on year
Segment Latestquarter on quarteryear on year
- Single Reportable$4.0M$4.0MQoQ +37%year on year +70%+37%+70%